Maxim Group reissued their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a research note published on Wednesday, February 7th. They currently have a $52.00 price objective on the stock.
“On January 29th, BeyondSpring hosted a KOL call to discuss its lead asset, Plinabulin. Dr. Douglas Blayney, a founding member of the NCCN neutropenia management guideline panel, spoke on the call regarding Plinabulin and the ongoing phase 2/3 trial, Study 105 for the prevention of docetaxel chemotherapy-induced neutropenia (CIN).”,” Maxim Group’s analyst commented.
BYSI has been the topic of several other research reports. Zacks Investment Research raised Beyondspring from a sell rating to a hold rating in a research note on Tuesday, January 9th. HC Wainwright set a $60.00 price objective on Beyondspring and gave the stock a buy rating in a research note on Monday, December 4th. Finally, Seaport Global Securities initiated coverage on Beyondspring in a research note on Tuesday, December 5th. They issued a buy rating and a $56.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $54.50.
Shares of Beyondspring (BYSI) opened at $24.99 on Wednesday. Beyondspring has a 12 month low of $16.55 and a 12 month high of $48.49.
A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in shares of Beyondspring Inc (NASDAQ:BYSI) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring makes up approximately 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned 0.10% of Beyondspring as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.22% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/24/maxim-group-reiterates-buy-rating-for-beyondspring-bysi.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.